Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: The omega-3 fatty acids randomized long-term (ORL) study

Journal of Clinical Lipidology

Volumn 7, Issue 6, 2013, Pages 615-625

  Tatsuno, Ichiro ^a   Saito, Yasushi ^b   Kudou, Kentarou ^c   Ootake, Jun ^c  

^a National Hospital Organization   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Docosahexaenoic acid; Dyslipidemia; Eicosapentaenoic acid; Hypertriglyceridemia; Omega 3 fatty acid; TAK 085

Indexed keywords

ICOSAPENTAENOIC ACID ETHYL ESTER; OMEGA 3 ACID ETHYL ESTER; TRIACYLGLYCEROL;

ADULT; AGED; ALLERGIC CONJUNCTIVITIS; ALLERGIC RHINITIS; ALLERGY; ARTHRALGIA; ARTICLE; BACKACHE; BODY WEIGHT; BRONCHITIS; CONSTIPATION; CONTROLLED STUDY; CONTUSION; CREATINE KINASE BLOOD LEVEL; DENTAL CARIES; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ECZEMA; ENTEROCOLITIS; FALLING; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTRITIS; GASTROENTERITIS; HEADACHE; HUMAN; HYPERTRIGLYCERIDEMIA; HYPESTHESIA; INFLUENZA; LIFESTYLE MODIFICATION; LIMB PAIN; LIVER FUNCTION TEST; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OPEN STUDY; OROPHARYNX PAIN; OSTEOARTHRITIS; PERIODONTITIS; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; RHINOPHARYNGITIS; SIDE EFFECT; TRAFFIC ACCIDENT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; URIC ACID BLOOD LEVEL; URTICARIA; VITAL SIGN;

DOCOSAHEXAENOIC ACID; DYSLIPIDEMIA; EICOSAPENTAENOIC ACID; HYPERTRIGLYCERIDEMIA; OMEGA-3 FATTY ACID; TAK-085;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DIET; DOCOSAHEXAENOIC ACIDS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; EICOSAPENTAENOIC ACID; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; JAPAN; LIFE STYLE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84889686400     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2013.09.002     Document Type: Article

References (31)

1. G. Assman, H. Schulte, and A. von Eckardstein Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men Am J Cardiol 77 1996 1179 1184
2. J.E. Hokanson, and M.A. Austin Plasma triglyceride levels is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol levels: a meta-analysis of population-based prospective studies J Cardiovasc Risk 3 1996 213 219
3. B.G. Nordestgaard, M. Benn, P. Schnohr, and A. Tybjaerg-Hansen Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women JAMA 298 2007 299 308
4. M. Miller, C.P. Cannon, S.A. Murphy, J. Qin, K.K. Ray, E. Braunwald on behalf of the PROVE IT-TIMI 22 Investigators Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial J Am Coll Cardiol 51 2008 724 730
5. H.E. Bays, A.P. Tighe, R. Sadovsky, and M.H. Davidson Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications Expert Rev Cardiovasc Ther 6 2008 391 409
6. W.S. Harris n-3 Fatty acids and serum lipoproteins: human studies Am J Clin Nutr 65 5 Suppl 1997 1645S 1654S
7. M.L. Burr, A.M. Fehily, and J.F. Gilbert Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART) Lancet 334 1989 757 761
8. GISSI-Prevenzione Investigators Dietary supplementation with n-3 polyunsaturated fatty acids with vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial Lancet 354 1999 447 455
9. C. Wang, W.S. Harris, and M. Chung n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review Am J Clin Nutr 84 2006 5 17
10. H. Iso, M. Kobayashi, J. Ishihara JPHC Study Group Intake of fish and n3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-Based (JPHC) Study Cohort I Circulation 113 2006 195 202
11. M. Yokoyama, H. Origasa, M. Matsuzaki for the Japan EPA lipid intervention study (JELIS) Investigators Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis Lancet 369 2007 1090 1098
12. I. Tatsuno, Y. Saito, K. Kudou, and J. Otake Efficacy and safety of TAK-085 in comparison with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification J Clin Lipidol 7 2013 199 207
13. T. Teramoto, J. Sasaki, and H. Ueshima Goals of dyslipidemia management - executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese J Atheroscler Thromb 14 2007 209 212
14. Ministry of Health and Welfare. Sample size and duration of treatment in clinical study for evaluation of the safety of new pharmaceuticals expected to be used for a long period in the subjects with non-fatal diseases. Tokyo, Japan: Evaluation and Licensing Division, Pharmaceutical and Medical Safety Bureau, Ministry of Health and WelfareW; May 1995. Notification No. 592.
15. ICH Harmonised Tripartite Guideline. The extent of population exposure to assess clinical safety for drugs intended for long-term treatment of non-life-threatening conditions E1. Available at: http:// www.ich.org. Accessed June15, 2012.
16. M.J. Chapman, H.N. Ginsberg, P. Amarenco, F. Andreotti, J. Borén, A.L. Catapano European Atherosclerosis Society Consensus Panel Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Eur Heart J 32 2011 1345 1361
17. A. Varbo, B.G. Nordestgaard, A. Tybjaerg-Hansen, P. Schnohr, G.B. Jensen, and M. Benn Non-fasting triglycerides, cholesterol, and ischemic stroke in the general population Ann Neurol 69 2011 628 634
18. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
19. I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell European Society of Cardiology (ESC) Committee for Practice Guidelines (CPG) European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts) Eur Heart J 28 2007 2375 2414
20. W.S. Harris, M. Miller, A.P. Tighe, M.H. Davidson, and E.J. Schaefer Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives Atherosclerosis 197 2008 12 24
21. A.F. Cicero, G. Derosa, V. Di Gregori, M. Bove, A.V. Gaddi, and C. Borghi Omega 3 polyunsaturated fatty acids supplementation and blood pressure levels in hypertriglyceridemic patients with untreated normal-high blood pressure and with or without metabolic syndrome: a retrospective study Clin Exp Hypertens 32 2010 137 144
22. P.G. Schmitz, L.K. McCloud, S.T. Reikes, C.L. Leonard, and M.E. Gellens Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomized, prospective trial J Am Soc Nephrol 13 2002 184 190
23. R. Marchioli, F. Barzi, E. Bomba, C. Chieffo, D. Di Gregorio, R. Di Mascio GISSI-Prevenzione Investigators Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione Circulation 105 2002 1897 1903
24. K. Mayer, M. Merfels, and M. Muhly-Reinholz Omega-3 fatty acids suppress monocyte adhesion to human endothelial cells: role of endothelial PAF generation Am J Physiol Heart Circ Physiol 283 2002 H811 H818
25. T.A. Mori, and L.J. Beilin Omega-3 fatty acids and inflammation Curr Atheroscler Rep 6 2004 461 467
26. E.M. Balk, A.H. Lichtenstein, M. Chung, B. Kupelnick, P. Chew, and J. Lau Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review Atherosclerosis 189 2006 19 30
27. J.M. McKenney, and D. Sica Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia Am J Health Syst Pharm 64 2007 595 605
28. H.E. Bays, K.C. Maki, and J. Mckenney Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients Curr Med Res Opin 26 2010 907 915
29. W.S. Harris, H.N. Ginsberg, and N. Arunakul Safety and efficacy of Omacor in severe hypertiglyceridemia J Cardiovasc Risk 4 1997 385 391
30. L. Borthwick The effects of omega-3 ethyl ester concentrate on blood lipid concentrations in patients with hyperlipidaemia Clin Drug Invest 15 1998 397 404
31. M.H. Davidson, E.A. Stein, H.E. Bays COMBination of prescription Omega-3 with Simvastatin (COMBOS)Investigators Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study Clin Ther 29 2007 1354 1367